Literature DB >> 19460682

Characterizing aggressiveness and predicting future progression of CF lung disease.

Michael W Konstan1, Jeffrey S Wagener, Donald R VanDevanter.   

Abstract

Cystic fibrosis (CF) is a life-shortening genetic disease characterized by variability in age of death that is largely due to variability in rate of progression of lung disease, the primary cause of mortality. Recognizing which individuals have more aggressive disease phenotypes and predicting their risk of immediate lung disease progression is a critical step in managing CF lung disease and extending the life expectancy of CF patients. Studies using observational CF patient registries have yielded useful methods for predicting future rate of disease progression and can be used to determine the impact that chronic pulmonary therapies have on slowing rate of lung function decline.

Entities:  

Mesh:

Year:  2009        PMID: 19460682      PMCID: PMC4167362          DOI: 10.1016/S1569-1993(09)60006-0

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  15 in total

Review 1.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

2.  Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada.

Authors:  W J Morgan; S M Butler; C A Johnson; A A Colin; S C FitzSimmons; D E Geller; M W Konstan; M J Light; H R Rabin; W E Regelmann; D V Schidlow; D C Stokes; M E Wohl; H Kaplowitz; M M Wyatt; S Stryker
Journal:  Pediatr Pulmonol       Date:  1999-10

3.  Identifying treatments that halt progression of pulmonary disease in cystic fibrosis.

Authors:  P B Davis; P J Byard; M W Konstan
Journal:  Pediatr Res       Date:  1997-02       Impact factor: 3.756

4.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

Authors:  M Corey; L Edwards; H Levison; M Knowles
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

Review 5.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.

Authors:  Scott D Grosse; Coleen A Boyle; Jeffrey R Botkin; Anne Marie Comeau; Martin Kharrazi; Margaret Rosenfeld; Benjamin S Wilfond
Journal:  MMWR Recomm Rep       Date:  2004-10-15

6.  Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis.

Authors:  Michael W Konstan; Steven M Butler; Mary Ellen B Wohl; Marcia Stoddard; Robert Matousek; Jeffrey S Wagener; Charles A Johnson; Wayne J Morgan
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

7.  Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.

Authors:  Clement L Ren; David J Pasta; Lawrence Rasouliyan; Jeffrey S Wagener; Michael W Konstan; Wayne J Morgan
Journal:  J Pediatr       Date:  2008-08-30       Impact factor: 4.406

8.  Prediction of mortality in patients with cystic fibrosis.

Authors:  E Kerem; J Reisman; M Corey; G J Canny; H Levison
Journal:  N Engl J Med       Date:  1992-04-30       Impact factor: 91.245

9.  Effect of high-dose ibuprofen in patients with cystic fibrosis.

Authors:  M W Konstan; P J Byard; C L Hoppel; P B Davis
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

10.  Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.

Authors:  Mark D Schluchter; Michael W Konstan; Pamela B Davis
Journal:  Stat Med       Date:  2002-05-15       Impact factor: 2.373

View more
  22 in total

Review 1.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

2.  Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients.

Authors:  Andrea Hahn; Caroline Jensen; Hani Fanous; Hollis Chaney; Iman Sami; Geovanny F Perez; Stan Louie; Anastassios C Koumbourlis; James E Bost; John N van den Anker
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

3.  Decade-long bacterial community dynamics in cystic fibrosis airways.

Authors:  Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

4.  Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012.

Authors:  Donald R VanDevanter; David J Pasta; Michael W Konstan
Journal:  J Pediatr       Date:  2014-08-16       Impact factor: 4.406

5.  Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis.

Authors:  Michael W Konstan; Felix Ratjen
Journal:  J Cyst Fibros       Date:  2011-11-16       Impact factor: 5.482

6.  Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.

Authors:  Donald R VanDevanter; Jeffrey S Wagener; David J Pasta; Eric Elkin; Joan R Jacobs; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2010-08-17

7.  Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

Authors:  Donald R VanDevanter; Michael W Konstan
Journal:  Clin Investig (Lond)       Date:  2012

8.  Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Authors:  David Taylor-Robinson; Margaret Whitehead; Finn Diderichsen; Hanne Vebert Olesen; Tania Pressler; Rosalind L Smyth; Peter Diggle
Journal:  Thorax       Date:  2012-05-03       Impact factor: 9.139

9.  The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis.

Authors:  David A Ngan; Pearce G Wilcox; May Aldaabil; Yuexin Li; Jonathon A Leipsic; Don D Sin; S F Paul Man
Journal:  BMC Pulm Med       Date:  2012-02-14       Impact factor: 3.317

10.  Prevotella melaninogenica, a Sentinel Species of Antibiotic Resistance in Cystic Fibrosis Respiratory Niche?

Authors:  Claudie Lamoureux; Charles-Antoine Guilloux; Elise Courteboeuf; Stéphanie Gouriou; Clémence Beauruelle; Geneviève Héry-Arnaud
Journal:  Microorganisms       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.